98 related articles for article (PubMed ID: 9577556)
21. Interleukin-4-receptor alpha gene polymorphism and the risk of renal cell carcinoma in a South Indian population.
Mohan S; Mohanasenthil ; Paul SF; Shroff S; Venkatesan V
Asian Pac J Cancer Prev; 2009; 10(2):295-8. PubMed ID: 19548368
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of vitamin D receptor and retinoid X receptor expression in renal cell carcinoma.
Obara W; Konda R; Akasaka S; Nakamura S; Sugawara A; Fujioka T
J Urol; 2007 Oct; 178(4 Pt 1):1497-503. PubMed ID: 17707062
[TBL] [Abstract][Full Text] [Related]
23. Predictive role of vascular endothelial growth factor polymorphisms in the survival of renal cell carcinoma patients.
Yang YQ; Chen J
Genet Mol Res; 2014 Jul; 13(3):5011-7. PubMed ID: 25062489
[TBL] [Abstract][Full Text] [Related]
24. PCR-based RFLP screening of the commonly deleted 3p loci in renal cortical neoplasms.
el-Naggar AK; Batsakis JG; Wang G; Lee MS
Diagn Mol Pathol; 1993 Dec; 2(4):269-76. PubMed ID: 7906993
[TBL] [Abstract][Full Text] [Related]
25. The gene polymorphism of tumor necrosis factor-beta, but not that of tumor necrosis factor-alpha, is associated with the prognosis of sarcoidosis.
Yamaguchi E; Itoh A; Hizawa N; Kawakami Y
Chest; 2001 Mar; 119(3):753-61. PubMed ID: 11243953
[TBL] [Abstract][Full Text] [Related]
26. The CASP8 -652 6N insertion/deletion promoter polymorphism is associated with renal cell carcinoma risk and metastasis.
de Martino M; Haitel A; Schatzl G; Klingler HC; Klatte T
J Urol; 2013 Aug; 190(2):717-22. PubMed ID: 23313206
[TBL] [Abstract][Full Text] [Related]
27. Association of tumour necrosis factor-α polymorphism in patients with end stage renal disease.
Singh K; Prasad KN; Mishra P; Singh SK; Kharwar NK; Prasad N; Gupta A; Srivastava JK
Nephrology (Carlton); 2015 Jun; 20(6):387-91. PubMed ID: 25589331
[TBL] [Abstract][Full Text] [Related]
28. TNF-α augments CXCR2 and CXCR3 to promote progression of renal cell carcinoma.
Sun KH; Sun GH; Wu YC; Ko BJ; Hsu HT; Wu ST
J Cell Mol Med; 2016 Nov; 20(11):2020-2028. PubMed ID: 27297979
[TBL] [Abstract][Full Text] [Related]
29. Expression profiling and clinicopathological significance of DNA methyltransferase 1, 3A and 3B in sporadic human renal cell carcinoma.
Li M; Wang Y; Song Y; Bu R; Yin B; Fei X; Guo Q; Wu B
Int J Clin Exp Pathol; 2014; 7(11):7597-609. PubMed ID: 25550796
[TBL] [Abstract][Full Text] [Related]
30. Limited prognostic value of tumor necrosis in patients with renal cell carcinoma.
Isbarn H; Patard JJ; Lughezzani G; Rioux-Leclercq N; Crépel M; Cindolo L; de la Taille A; Zini L; Villers A; Shariat SF; Bertini R; Karakiewicz PI
Urology; 2010 Jun; 75(6):1378-84. PubMed ID: 19781745
[TBL] [Abstract][Full Text] [Related]
31. Genetic polymorphisms of the interleukin-4 receptor alpha gene are associated with an increasing risk and a poor prognosis of sporadic renal cell carcinoma in a Japanese population.
Nakamura E; Megumi Y; Kobayashi T; Kamoto T; Ishitoya S; Terachi T; Tachibana M; Matsushiro H; Habuchi T; Kakehi Y; Ogawa O
Clin Cancer Res; 2002 Aug; 8(8):2620-5. PubMed ID: 12171893
[TBL] [Abstract][Full Text] [Related]
32. Prognostic implications of cytogenetic findings in kidney cancer.
Elfving P; Mandahl N; Lundgren R; Limon J; Bak-Jensen E; Fernö M; Olsson H; Mitelman F
Br J Urol; 1997 Nov; 80(5):698-706. PubMed ID: 9393289
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of CD31 (PECAM-1) expression using tissue microarray in patients with renal cell carcinoma.
Sandlund J; Hedberg Y; Bergh A; Grankvist K; Ljungberg B; Rasmuson T
Tumour Biol; 2007; 28(3):158-64. PubMed ID: 17510564
[TBL] [Abstract][Full Text] [Related]
34. Anillin expression is a marker of favourable prognosis in patients with renal cell carcinoma.
Ronkainen H; Hirvikoski P; Kauppila S; Vaarala MH
Oncol Rep; 2011 Jan; 25(1):129-33. PubMed ID: 21109967
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia-inducible factor-2alpha mRNA expression in human renal cell carcinoma.
Sandlund J; Ljungberg B; Wikström P; Grankvist K; Lindh G; Rasmuson T
Acta Oncol; 2009; 48(6):909-14. PubMed ID: 19322701
[TBL] [Abstract][Full Text] [Related]
36. Role of the STK15 Phe31Ile polymorphism in renal cell carcinoma.
Hammerschmied CG; Stoehr R; Walter B; Wieland WF; Hartmann A; Blaszyk H; Denzinger S
Oncol Rep; 2007 Jan; 17(1):3-7. PubMed ID: 17143471
[TBL] [Abstract][Full Text] [Related]
37. Possible correlation between polymorphism in the tumor necrosis factor-beta gene and the clinicopathological features of bladder cancer in Japanese patients.
Nonomura N; Tokizane T; Nakayama M; Inoue H; Nishimura K; Muramatsu M; Okuyama A
Int J Urol; 2006 Jul; 13(7):971-6. PubMed ID: 16882065
[TBL] [Abstract][Full Text] [Related]
38. The correlation between the loss of chromosome 14q with histologic tumor grade, pathologic stage, and outcome of patients with nonpapillary renal cell carcinoma.
Wu SQ; Hafez GR; Xing W; Newton M; Chen XR; Messing E
Cancer; 1996 Mar; 77(6):1154-60. PubMed ID: 8635138
[TBL] [Abstract][Full Text] [Related]
39. Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance.
Mizutani Y; Nakanishi H; Yamamoto K; Li YN; Matsubara H; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
J Clin Oncol; 2005 Jan; 23(3):448-54. PubMed ID: 15572731
[TBL] [Abstract][Full Text] [Related]
40. [Serum levels and gene expressions of interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) in human renal cell carcinomas].
Hamao T; Kanayama H; Kan M; Takigawa H; Kagawa S
Nihon Hinyokika Gakkai Zasshi; 1994 Apr; 85(4):563-70. PubMed ID: 8189655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
